ABBV · News · 20261102N

QULIPTA Migraine Trial Results

AbbVie Inc. · 2026-11-02 · Importance 34 · Surprise 42

AbbVie reported positive Phase 3 TEMPLE trial results for QULIPTA in migraine prevention, published in The Lancet Neurology. QULIPTA showed superior migraine-prevention efficacy compared with topiramate, a widely used oral therapy. Investigators also reported improved tolerability versus topiramate, potentially addressing a common reason patients discontinue preventive migraine treatment.

Key facts

• AbbVie’s 2024 exclusive license agreement with Brise assigns Brise discovery efforts and AbbVie global development and commercialization for two of Brise’s preclinical migraine programs. source
• AbbVie reported positive Phase 3 TEMPLE trial results for QULIPTA in migraine prevention; QULIPTA achieved superior migraine prevention efficacy and improved tolerability compared with topiramate. source